[Effect of antioxidant use in dietary therapy in patients with chronic athrofic hastritis].
In the 1-year double-blind placebo-controlled intervention trial, it was shown that daily supplementation of patients with gastric premalignant lesions (intestinal metaplasia, IM) with a complex, containing Ester-C with antioxidantsand (2100 mg of Ca-ascorbate + 340 mg of bioflavonoids), produced a sharp decrease of abnormally high ornithine decarboxylase activity in IM gastric mucosa that was accom panied by practically total IM regression in 11 of 18 (61%) patients.
Draudin-Krylenko
V A
VA
Petukhov
A B
AB
Kuvshinov
Iu P
IuP
Levchuk
A A
AA
Bukin
Iu V
IuV
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage*; D001205:Ascorbic Acid / Q000008:administration & dosage*; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D005753:Gastric Mucosa / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D005757:Gastritis, Atrophic / Q000178:diet therapy* / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016481:Helicobacter Infections / Q000178:diet therapy* / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007422:Intestines / Q000201:enzymology / Q000473:pathology; D008297:Male; D008679:Metaplasia / Q000178:diet therapy / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D008875:Middle Aged; D009955:Ornithine Decarboxylase / Q000378:metabolism
D000975:Antioxidants; D009955:Ornithine Decarboxylase; D001205:Ascorbic Acid